|Bid||7.94 x 2200|
|Ask||7.92 x 1800|
|Day's Range||6.71 - 8.12|
|52 Week Range||4.26 - 15.65|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.14|
During Q4, Syros Pharmaceuticals's (NASDAQ:SYRS) reported sales totaled $5.70 million. Despite a 53.81% in earnings, the company posted a loss of $29.22 million. In Q3, Syros Pharmaceuticals brought in $3.83 million in sales but lost $19.00 million in earnings. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Syros Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Syros Pharmaceuticals posted an ROCE of -0.32%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future. View more earnings on SYRS ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Syros Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. For Syros Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions. Q4 Earnings Insight Syros Pharmaceuticals reported Q4 earnings per share at $-0.62/share, which did not meet analyst predictions of $-0.5/share. See more from BenzingaClick here for options trades from BenzingaRecap: Syros Pharmaceuticals Q4 EarningsEarnings Scheduled For March 4, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -12.96% and 78.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) rose 2.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 34.78% over the past year to ($0.62), which missed the estimate of ($0.50). Revenue of $5,698,000 up by 1021.65% year over year, which beat the estimate of $2,700,000. Guidance Earnings guidance hasn't been issued by the company for now. Syros Pharmaceuticals hasn't issued any revenue guidance for the time being. How To Listen To The Conference Call Date: Mar 04, 2021 View more earnings on SYRS Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/u2m2ncg6 Technicals Company's 52-week high was at $15.65 Company's 52-week low was at $4.26 Price action over last quarter: Up 0.71% Company Profile Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. The Company operates only in the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 4, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.